O Papel do Fenofibrato no Manejo da Retinopatia Diabética: Uma Revisão Integrativa
DOI:
https://doi.org/10.36557/2674-8169.2025v7n11p1006-1025Palavras-chave:
Fenofibrato, Retinopatia diabética, Diabetes mellitus tipo 2, BiofarmacologiaResumo
Objetivo: Integrar e sintetizar evidências sobre o uso do fenofibrato na retinopatia diabética (RD), considerando eficácia, segurança e mecanismos de ação. Métodos: Revisão integrativa de literatura em bases biomédicas, com análise de 42 estudos após deduplicação. As evidências foram comparadas de forma crítica, destacando convergências e divergências entre ensaios clínicos, revisões e estudos experimentais. Resultados: Ensaios como FIELD, ACCORD-EYE e LENS indicam redução consistente da progressão da RD em pacientes com DM2 e doença estabelecida, enquanto populações mistas apresentam efeitos limitados. Evidências apontam benefício no edema macular, sustentado por plausibilidade biológica envolvendo mecanismos anti-inflamatórios, antiangiogênicos e neuroprotetores. Contudo, eventos adversos renais permanecem como limitação, embora frequentemente reversíveis. A heterogeneidade metodológica e a escassez de desfechos funcionais robustos limitam a generalização. Conclusões: O fenofibrato emerge como adjuvante promissor no manejo da RD além do controle glicêmico, mas seu papel ainda demanda estudos em DM1, biomarcadores preditivos e desfechos centrados em visão e qualidade de vida.
Downloads
Referências
ABCOUWER, S. F. Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy. Diabetes, v. 62, n. 1, p. 36-38, 2013. Disponível em: https://doi.org/10.2337/db12-1223. Acesso em: 30 ago. 2025.
BELFORT, Renata et al. Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. The Journal of Clinical Endocrinology and Metabolism, v. 95, n. 2, p. 829–836, fev. 2010.
BOGDANOV, P. et al. Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetologica, v. 52, n. 1, p. 113-122, 2015. Disponível em: https://doi.org/10.1007/s00592-014-0610-2. Acesso em: 30 ago. 2025.
BONDS, D. E. et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia, v. 55, n. 6, p. 1641-1650, 2012. Disponível em: https://doi.org/10.1007/s00125-012-2524-2. Acesso em: 30 ago. 2025.
BONORA, B. M. et al. Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. Diabetologia, v. 64, n. 10, p. 2334-2344, 2021. Disponível em: https://doi.org/10.1007/s00125-021-05532-1. Acesso em: 30 ago. 2025.
CASTRO, Barbara Bruna Abreu et al. Fenofibrato atenua a lipotoxicidade renal em camundongos uninefrectomizados com obesidade induzida por dieta rica em gordura. Brazilian Journal of Nephrology, v. 46, n. 4, p. e20230148, dez. 2024.
CEVEY, Ágata Carolina. Efecto del tratamiento conjunto con benznidazol y fenofibrato en la modulación de la disfunción ventricular y de la respuesta inflamatoria en la enfermedad de Chagas experimental. In: 23 fev. 2018. Disponível em: <https://www.semanticscholar.org/paper/Efecto-del-tratamiento-conjunto-con-benznidazol-y-y-Cevey/3477abfe0229c9b982f2a6bdc80f00e68cfcd423>. Acesso em: 30 ago. 2025
DAVIS, T. M. et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, v. 54, n. 2, p. 280-290, 2011. Disponível em: https://doi.org/10.1007/s00125-010-1951-1. Acesso em: 30 ago. 2025.
DISSANAYAKE, H. A. et al. The use of fenofibrate in diabetic retinopathy: Narrative review. Journal of Diabetes and its Complications, v. 39, n. 10, p. 109135, 2025. Disponível em: https://doi.org/10.1016/j.jdiacomp.2025.109135. Acesso em: 30 ago. 2025.
ENRIGHT, J. M. et al. Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression. Journal of Clinical Medicine, v. 10, n. 1, p. 126, 2020. Disponível em: https://doi.org/10.3390/jcm10010126. Acesso em: 30 ago. 2025.
FARNIER, Michel. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular Health and Risk Management, v. 4, n. 5, p. 991–1000, out. 2008.
GONG, Y. et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine, v. 13, p. 201-211, 2016. Disponível em: https://doi.org/10.1016/j.ebiom.2016.09.025. Acesso em: 30 ago. 2025.
HSU, Y. J. et al. Effects of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats. Journal of Diabetes Research, v. 2014, p. 540326, 2014. Disponível em: https://doi.org/10.1155/2014/540326. Acesso em: 30 ago. 2025.
HSU, Y. J. et al. Protective Effect of Fenofibrate on Oxidative Stress-Induced Apoptosis in Retinal-Choroidal Vascular Endothelial Cells: Implication for Diabetic Retinopathy Treatment. Antioxidants, Basel, v. 9, n. 8, p. 712, 2020. Disponível em: https://doi.org/10.3390/antiox9080712. Acesso em: 30 ago. 2025.
JANUSZEWSKI, A. S. et al. Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate. Journal of Diabetes Investigation, v. 15, n. 11, p. 1663-1668, 2024. Disponível em: https://doi.org/10.1111/jdi.14290. Acesso em: 30 ago. 2025.
JIN, Lv et al. Anti-inflammatory role of fenofibrate in treating diseases. Biomolecules and Biomedicine, v. 23, n. 3, p. 376–391, 1 jun. 2023.
JU, H. B. et al. Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. Medicine, Baltimore, v. 96, n. 31, p. e7671, 2017. Disponível em: https://doi.org/10.1097/MD.0000000000007671. Acesso em: 30 ago. 2025.
KATAOKA, S. Y. et al. Fenofibrate for diabetic retinopathy. Cochrane Database of Systematic Reviews, v. 2023, n. 6, p. CD013318.pub2, 2023. Disponível em: https://doi.org/10.1002/14651858.CD013318.pub2. Acesso em: 30 ago. 2025.
KEECH, A. C. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, v. 370, n. 9600, p. 1687-1697, 2007. Disponível em: https://doi.org/10.1016/S0140-6736(07)61607-9. Acesso em: 30 ago. 2025.
KOCIOK, N. et al. Effects of fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier. Acta Diabetologica, v. 57, n. 12, p. 1423-1433, 2020. Disponível em: https://doi.org/10.1007/s00592-020-01565-x. Acesso em: 30 ago. 2025.
KRAJA, Aldi T. et al. Fenofibrate and Metabolic Syndrome. Endocrine, metabolic & immune disorders drug targets, v. 10, n. 2, p. 138–148, jun. 2010.
LEE, D. et al. Fenofibrate Protects against Retinal Dysfunction in a Murine Model of Common Carotid Artery Occlusion-Induced Ocular Ischemia. Pharmaceuticals, Basel, v. 14, n. 3, p. 223, 2021. Disponível em: https://doi.org/10.3390/ph14030223. Acesso em: 30 ago. 2025.
LI, J. et al. Fenofibrate Ameliorates Oxidative Stress-Induced Retinal Microvascular Dysfunction in Diabetic Rats. Current Eye Research, v. 43, n. 11, p. 1395-1403, 2018. Disponível em: https://doi.org/10.1080/02713683.2018.1501072. Acesso em: 30 ago. 2025.
LIN, R. et al. Fenofibrate-Induced Osmotic Nephropathy: A Novel Mechanism of Acute Kidney Injury. American Journal of Kidney Diseases, v. 86, n. 3, p. 404-407, 2025. Disponível em: https://doi.org/10.1053/j.ajkd.2025.03.019. Acesso em: 30 ago. 2025.
LING, Hua; LUOMA, John T.; HILLEMAN, Daniel. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiology Research, v. 4, n. 2, p. 47–55, abr. 2013.
LIU, Y. C. et al. Comment on: "Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial ". Eye, London, v. 39, n. 10, p. 2106, 2025. Disponível em: https://doi.org/10.1038/s41433-025-03866-3. Acesso em: 30 ago. 2025.
MARQUES, F.; VIVEIRO, C.; CASTRO, I. Rabdomiólise induzida por fenofibrato em adolescente com insuficiência renal crónica e hipotiroidismo. portuguese journal of nephrology and hypertension, 1 set. 2014.
MEER, E. et al. Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmology, v. 140, n. 5, p. 529-532, 2022. Disponível em: https://doi.org/10.1001/jamaophthalmol.2022.0633. Acesso em: 30 ago. 2025.
MIRANDA, S. et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. Journal of Cellular Physiology, v. 227, n. 6, p. 2352-2362, 2012. Disponível em: https://doi.org/10.1002/jcp.22970. Acesso em: 30 ago. 2025.
MORETTO, A. Fenofibrato nella terapia del diabete. In: 27 set. 2016. Disponível em: <https://www.semanticscholar.org/paper/Fenofibrato-nella-terapia-del-diabete-Moretto/9d6b2784c99f81b60cb757d116dbdaf82a8ff7ac>. Acesso em: 30 ago. 2025
MYCHALECKYJ, J. C. et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care, v. 35, n. 5, p. 1008-1014, 2012. Disponível em: https://doi.org/10.2337/dc11-1811. Acesso em: 30 ago. 2025.
NGUYEN, H. et al. Randomised, multicentre, placebo-controlled trial of fenofibrate for treatment of diabetic macular oedema. Eye, London, 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11676638/. Acesso em: 30 ago. 2025.
NOONAN, Jonathan E. et al. An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes. Diabetes, v. 62, n. 12, p. 3968, 16 nov. 2013.
ONG, K. L. et al. Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy. Diabetes Research and Clinical Practice, v. 226, p. 112080, 2025. Disponível em: https://doi.org/10.1016/j.diabres.2025.112080. Acesso em: 30 ago. 2025.
PARK, Jiwon et al. Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes. Cardiovascular Diabetology, v. 23, p. 343, 16 set. 2024.
PINTÓ, Xavier. Indicaciones de la combinación de pravastatina y fenofibrato según el nivel de riesgo cardiovascular. Situaciones clínicas habituales. Clínica e Investigación en Arteriosclerosis, Pravastatina y fenofibrato: una combinación para la dislipemia aterogénica. v. 26, p. 35–39, 1 jul. 2014.
PIRES, Sumaia Araújo. Estudos de compatibilidade dos fármacos fenofibrato, ciprofibrato e citalopram com alguns excipientes. In: 5 out. 2016. Disponível em: <https://www.semanticscholar.org/paper/Estudos-de-compatibilidade-dos-f%C3%A1rmacos-e-com-Pires/92c4aabf3f0eb94b493576b1a594aeceacdb7c78>. Acesso em: 30 ago. 2025
PREISS, D. et al. Effect of Fenofibrate on Progression of Diabetic Retinopathy. NEJM Evidence, v. 3, n. 8, p. EVIDoa2400179, 2024. Disponível em: https://doi.org/10.1056/EVIDoa2400179. Acesso em: 30 ago. 2025.
PREISS, D. et al. Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care, v. 45, n. 1, p. e1-e2, 2022. Disponível em: https://doi.org/10.2337/dc21-1439. Acesso em: 30 ago. 2025.
REDUCING ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits. Cardiovascular Journal of Africa, v. 18, n. 6, p. 400, 2007. Disponível em: https://pubmed.ncbi.nlm.nih.gov/18092120. Acesso em: 30 ago. 2025.
RIVERA‐MEZA, Mario et al. Fenofibrate -a PPARα agonist- increases alcohol dehydrogenase levels in the liver: implications for its possible use as an ethanol-aversive drug Fenofibrato -un agonista de PPARα- incrementa los niveles de la alcohol deshidrogenasa hepática: implicaciones. In: 2020. Disponível em: <https://www.semanticscholar.org/paper/Fenofibrate-a-PPAR%CE%B1-agonist-increases-alcohol-in-as-Rivera%E2%80%90Meza-Flores-Bast%C3%ADas/d60ac95ff8c2cc777338e99152dcd3d585013fcc>. Acesso em: 30 ago. 2025
RODRÍGUEZ, Ángel Díaz. Combinación fija pravastatina/fenofibrato: ¿qué puede aportar? Clínica e Investigación en Arteriosclerosis, Pravastatina y fenofibrato: una combinación para la dislipemia aterogénica. v. 26, p. 12–16, 1 jul. 2014.
SAÚDE, Núcleo de Avaliação de Tecnologias em. RR 161 - 2014 NATS Memantina, Exelon, Niar, Prolopa,Lipanon (fenofibrato). In: 31 mar. 2014. Disponível em: <https://www.semanticscholar.org/paper/RR-161-2014-NATS-Memantina%2C-Exelon%2C-Niar%2C-Sa%C3%BAde/4ba1a6702803bc4114e1939a1063c3d2a80b3159>. Acesso em: 30 ago. 2025
SCOTLAND, G. et al. Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial. Diabetic Medicine, v. 42, n. 9, p. e70098, 2025. Disponível em: https://doi.org/10.1111/dme.70098. Acesso em: 30 ago. 2025.
SEGARRA, Cristina Gili. No todo es COVID-19. Toxicidad por fenofibrato. FMC - Formación Médica Continuada en Atención Primaria, v. 29, n. 2, p. 76–79, 1 fev. 2022.
SHI, Y. et al. Fenofibrate mitigates the dysfunction of high glucose-driven human retinal microvascular endothelial cells by suppressing NLRP3 inflammasome. International Journal of Ophthalmology, v. 18, n. 5, p. 792-801, 2025. Disponível em: https://doi.org/10.18240/ijo.2025.05.04. Acesso em: 30 ago. 2025.
SILVA, P. S.; AIELLO, L. P. Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression. NEJM Evidence, v. 3, n. 8, p. EVIDe2400205, 2024. Disponível em: https://doi.org/10.1056/EVIDe2400205. Acesso em: 30 ago. 2025.
SIMÓ, R. et al. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Current Medicinal Chemistry, v. 20, n. 26, p. 3258-3266, 2013. Disponível em: https://doi.org/10.2174/0929867311320260009. Acesso em: 30 ago. 2025.
SIMÓ, R.; HERNÁNDEZ, C. Fenofibrate for diabetic retinopathy. Lancet, v. 370, n. 9600, p. 1667-1668, 2007. Disponível em: https://doi.org/10.1016/S0140-6736(07)61608-0. Acesso em: 30 ago. 2025.
SIMÓ, R.; HERNÁNDEZ, C. Fenofibrato en el tratamiento de la retinopatía diabética. Medicina Clínica, Barcelona, v. 131, n. 1, p. 16-17, 2008. Disponível em: https://doi.org/10.1157/13123045. Acesso em: 30 ago. 2025.
SRINIVASAN, S. et al. Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. Indian Journal of Ophthalmology, v. 66, n. 1, p. 98-105, 2018. Disponível em: https://doi.org/10.4103/ijo.IJO_566_17. Acesso em: 30 ago. 2025.
TING, R. D. et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care, v. 35, n. 2, p. 218-225, 2012. Disponível em: https://doi.org/10.2337/dc11-1109. Acesso em: 30 ago. 2025.
UCHIDA, Aki et al. Fenofibrate, A Peroxisome Proliferator-Activated Receptor α Agonist, Alters Triglyceride Metabolism In Enterocytes of Mice. Biochimica et biophysica acta, v. 1811, n. 3, p. 170–176, mar. 2011.
VARUGHESE, M. S. et al. Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial. Eye, London, v. 39, n. 10, p. 2106, 2025. Disponível em: https://doi.org/10.1038/s41433-025-03866-3. Acesso em: 30 ago. 2025.
WANG, N. et al. Fenofibrate Exerts Protective Effects in Diabetic Retinopathy via Inhibition of the ANGPTL3 Pathway. Investigative Ophthalmology & Visual Science, v. 59, n. 10, p. 4210-4217, 2018. Disponível em: https://doi.org/10.1167/iovs.18-24155. Acesso em: 30 ago. 2025.
WANG, Xue et al. Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice. Frontiers in Cellular and Infection Microbiology, v. 12, p. 839592, 2 jun. 2022.
WONG, T. Y. et al. Fenofibrate - a potential systemic treatment for diabetic retinopathy? American Journal of Ophthalmology, v. 154, n. 1, p. 6-12, 2012. Disponível em: https://doi.org/10.1016/j.ajo.2012.02.020. Acesso em: 30 ago. 2025.
WRIGHT, A. D.; DODSON, P. M. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye, London, v. 25, n. 7, p. 843-849, 2011. Disponível em: https://doi.org/10.1038/eye.2011.66. Acesso em: 30 ago. 2025.
YE, J. et al. Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity. Acta Diabetologica, v. 53, n. 1, p. 109-118, 2016. Disponível em: https://doi.org/10.1007/s00592-015-0759-3. Acesso em: 30 ago. 2025.
YEH, P. T. et al. Effect of Fenofibrate on the Expression of Inflammatory Mediators in a Diabetic Rat Model. Current Eye Research, v. 44, n. 10, p. 1121-1132, 2019. Disponível em: https://doi.org/10.1080/02713683.2019.1622020. Acesso em: 30 ago. 2025.
ZAYED, M. G. et al. Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis. JAMA Ophthalmology, v. 142, n. 3, p. 199-207, 2024. Disponível em: https://doi.org/10.1001/jamaophthalmol.2023.6435. Acesso em: 30 ago. 2025.
ZHANG, Ying et al. Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet. Frontiers in Nutrition, v. 9, p. 971581, 12 set. 2022.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2025 Rama Valente Lourenço, Luiza Gabriela Alves Gomes, Joyce Helena Leão Queiroz, Ana Karolina Ferreira Pereira , Luiz Filipe Matos da Silva, Igor Tadeu de Castro Nascimento, Fernanda Myllena Sousa Campos, Ana Paula Barata do Vale, Jefferson Lazarini de Aquino , Gabriel Maia Franco , Luís Fernando Damasceno
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os autores são detentores dos direitos autorais mediante uma licença CCBY 4.0.
